This CPG Company Achieves Substantial Fiscal 2023 Revenue & EBITDA Growth
Portfolio Pulse from Joana Scopel
Delivra Health Brands Inc. reported a 20% increase in net revenue and a 119% improvement in adjusted EBITDA for fiscal 2023. The growth was attributed to higher sales in the USA, a stronger gross margin, and overall expense reduction. The company also announced a strategic licensing agreement with a subsidiary of Canopy Growth Corporation to manufacture, distribute, and sell LivRelief brand-infused topical products in Canada.
October 18, 2023 | 7:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canopy Growth Corporation's subsidiary has entered into a strategic licensing agreement with Delivra Health Brands, which could potentially expand its product portfolio and market reach.
The strategic licensing agreement with Delivra Health Brands could potentially expand Canopy Growth Corporation's product portfolio and market reach, which could positively impact its stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Delivra Health Brands reported strong financial results for fiscal 2023, which could positively impact its stock price.
The company's strong financial performance and strategic partnership with Canopy Growth Corporation could increase investor confidence and drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100